IN 1966, Parkman, Meyer, and their colleagues described preliminary vaccine trials with a strain of rubella virus which had been attenuated by 77 passages in primary African green monkey kidney (AGMK) tissue culture.1,2 This strain, designated HPV-77, exhibited desirable qualities of immunogenicity and obvious attenuation in man. The present report describes our experience with HPV-77 virus in a series of vaccine trials which involved 48 children.
Materials and Methods
Vaccine.—The details of the preparation and safety testing of HPV-77 vaccine have been described by Meyer et al.1,2 The vaccine was supplied in single-dose vials which were stored at −65 C until use. Each vaccinated child received rubella vaccine (HPV-77), 0.5 ml subcutaneously. This dose represented 500 tissue culture interfering doses50 (TCID50), based on a titration in primary AGMK tissue culture using echovirus type 11 challenge.3Study Population and Experimental Design.—The 48 children were admitted
Cooper LZ, Giles JP, Krugman S. Clinical Trial of Live Attenuated Rubella Virus Vaccine, HPV-77 Strain. Am J Dis Child. 1968;115(6):655-657. doi:10.1001/archpedi.1968.02100010657003